Related Experiment Video
Updated: Jun 29, 2026
08:31
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
762
Oral Plasmablastic Lymphoma: Case Series and Literature Review
A Xu1, J P Foy1, P Reimbold2
1Sorbonne Université, Department of Maxillo-Facial Surgery, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France.
Head & Neck
|September 30, 2025
Summary
Plasmablastic lymphoma (PBL) is an aggressive oral cancer mainly affecting immunocompromised individuals, often linked to HIV. Early detection and new therapies are crucial, but prognosis remains poor for this rare malignancy.
Area of Science:
- Oncology
- Hematology
- Oral Pathology
Background:
- Plasmablastic lymphoma (PBL) is a rare, aggressive Non-Hodgkin lymphoma subtype.
- Predominantly affects immunocompromised individuals, especially those with Human Immunodeficiency Virus (HIV).
- Strong association with Epstein-Barr virus (EBV) suggests an oncogenic role.
Purpose of the Study:
- To present 11 cases of oral cavity PBL (OPBL).
- To detail clinical, radiological, pathological, and therapeutic features.
- To synthesize current evidence through a literature review.
Main Methods:
- Retrospective case series of 11 OPBL patients.
- Comprehensive literature review on oral cavity PBL.
Main Results:
- 645 OPBL cases reported since 2008, primarily in immunocompromised men with HIV.
- Maxillary alveolar ridge is the most common site, often with osteolytic bone lesions.
- Chemotherapy is standard, but novel therapies are emerging; prognosis remains poor.
Conclusions:
- Oral cavity plasmablastic lymphoma requires systematic consideration in immunocompromised patients.
- Submucosal lesions in immunocompromised individuals warrant investigation for OPBL.
- Further research into novel targeted therapies is needed for improved outcomes.
